1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CureVac N.V.

CureVac N.V.

5CV.F
CureVac N.V.undefined flagFrankfurt Stock Exchange
3.91
EUR
- -
- -
879.52MMarket Cap
CureVac N.V.
5CV.F
(Frankfurt Stock Exchange)

Recent

price

3.91

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
TTM
FRC
0.07
0.1
0.27
0.55
0.36
0.24
2.39
0.31
Revenue per Share
-0.4
-0.57
-0.72
-2.21
-1.32
-1.18
0.72
0.57
Basic EPS, GAAP
-0.5
-0.56
2.63
-4.63
-2.01
-1.46
0.37
-0.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.36
-2.87
-3.45
-5.56
-6.78
-6.97
-6.14
-5.39
Book Value per Share
0.15
-0.28
3.86
3.63
2.65
2.21
2.99
3.76
Tangible Book Value per Share
176
176
180
186
189
221
224
225
Basic Weighted Avg Shares
13
17
49
103
67
54
535
71
Sales/Revenue/Turnover
-565.8
-571.3
-224.7
-400.29
-370
-510.08
33.2
215.93
Operating Margin (%)
4
7
11
16
24
23
19
18
Depreciation Expense
-71
-100
-129
-412
-249
-260
162
129
Net Income, GAAP
- -
- -
- -
- -
- -
- -
15.03
18.15
Effective Tax Rate (%)
-553.5
-573.46
-264.21
-399.76
-369.37
-483.96
30.3
182.11
Profit Margin (%)
45
29
1,142
582
428
292
454
637
Working Capital
- -
77
27
25
37
37
34
30
LT Debt
32
-43
711
688
533
517
697
871
Total Equity
- -
- -
- -
- -
- -
- -
22.99
14.39
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-11.44
-10.78
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
32
31
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
225
225
225
Market Capitalization
590
1,034
1,025

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
469
420
873
Cash, Cash Equivalents & STI
442
396
419
Accounts Receivable, Net
2
- -
20
Inventories
1
1
1
Total Current Liabilities
61
68
236
Payables & Accruals
28
26
51
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-351.2%
34.76%
Free Cash Flow
- -
-211.36%
-125.82%
Net Income, GAAP
- -
10.15%
-162.34%
Sales/Revenue/Turnover
- -
226.42%
895.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
7
8
16
23
54
2024
12
14
494
14
535
2025
1
1
54
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.27
-0.3
-0.22
- -
-1.18
2024
-0.31
-0.32
1.51
- -
0.72
2025
-0.23
-0.26
1.21
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
UCB S.A. (UCBJF)
Stemcell Holdings, Inc. (STMM)
Synaptogenix, Inc. (SNPX)
Aptose Biosciences Inc. (APTO)
Neith Corporation (6236.TWO)
Prestige BioPharma Limited (950210.KS)
Business
CureVac N.V. CureVac N.V. (Ticker: 5CV.F), a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, and founded in 2000, develops transformative medicines based on proprietary messenger RNA (mRNA) technology. The company focuses on prophylactic vaccines for infectious diseases including SARS-CoV-2 variants, influenza, and urinary tract infections caused by uropathogenic E. coli; oncology treatments such as off-the-shelf and personalized cancer precision immunotherapies targeting squamous non-small cell lung cancer and glioblastoma; and molecular therapies that enable cells to produce therapeutic proteins. CureVac optimizes mRNA constructs with customized 5’ and 3’ untranslated regions and open reading frames, supported by carrier molecules like lipid nanoparticles developed in partnership with Acuitas Therapeutics and Arcturus Therapeutics; it also offers the RNA Printer, an automated system for mRNA vaccine and therapeutic manufacturing. Operations span Germany, the Netherlands, Belgium, Switzerland, and the United States, with collaborations including GlaxoSmithKline (GSK) GSK plc for influenza and COVID-19 vaccines—restructured in 2024 into a licensing agreement providing CureVac €400 million upfront and up to €1.05 billion in milestones plus royalties—and ongoing patent litigation against Pfizer Pfizer Inc./BioNTech BioNTech SE. In June 2025, BioNTech announced a definitive all-stock acquisition of CureVac valued at approximately USD 1.25 billion, with German regulatory clearance granted by November 2025 ahead of an extraordinary general meeting.